Toyonaka, Japan

Manabu Fujitani

This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignee: Shionogi Company Limited. Active years: 2019-2020.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2019-2020

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Manabu Fujitani: Innovator in Antifungal Compounds

Introduction

Manabu Fujitani is a notable inventor based in Toyonaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antifungal compounds. With a total of 2 patents to his name, Fujitani's work has the potential to impact medical treatments significantly.

Latest Patents

Fujitani's latest patents include a Polyene macrolide derivative, specifically an Amphotericin B derivative. This compound features a 16th position (X) that can be a urea structure, cyclic structure, hydroxyalkyl, or substituted monoalkylcarbamoyl. The invention demonstrates antifungal activity, showcasing its potential for therapeutic applications.

Career Highlights

Fujitani is associated with Shionogi Company Limited, where he continues to innovate in the pharmaceutical sector. His work focuses on enhancing the efficacy of antifungal treatments, which is crucial for addressing various fungal infections.

Collaborations

Fujitani has collaborated with notable colleagues, including Hideki Sugimoto and Takafumi Ohara. These partnerships have likely contributed to the advancement of his research and the successful development of his patents.

Conclusion

Manabu Fujitani is a distinguished inventor whose work in antifungal compounds is paving the way for new medical treatments. His contributions to the field are invaluable, and his ongoing research promises to yield further innovations in pharmaceuticals.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…